Bristol-Myers Squibb's growth portfolio now accounts for 54.1% of revenues and achieved a 9% year-over-year increase in the first quarter of fiscal 2026, offsetting declines in its legacy products. Strategic partnerships, acquisitions, and strong sales of Opdivo Qvantig support ongoing portfolio renewal despite short-term intellectual property risks. While intermediate growth may be limited due to patent expirations on key drugs like Eliquis and Opdivo, the company maintains secure dividend payouts at nearly 40% of free cash flow. The analyst reiterates a Buy rating, recommending accumulation for patient investors seeking inflation-beating income yields above 4.2%.
Bristol Myers Squibb (BMY) is rated a Strong Buy due to its steady performance and undervaluation, despite recent underperformance against the market benchmark. The company offers a 4.43% forward dividend yield, more than double the sector median, wi...
A bipartisan US congressional committee is investigating whether Merck, AbbVie, and three other major pharmaceutical companies conducted clinical trials in China that may have supported Chinese military capabilities. The inquiry focuses on due dilige...
